Ramesh Babu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ramesh Babu has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
Venkata Sai
Department of Radiology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India
11 shared publications- V. V. S. Chandrasekharam
Pediatric Urology, Pediatric Surgery & MAS, Ankura Hospitals for Women and Children, Hyderabad, India
10 shared publications - Nirmalan Shajini
Department of Paediatric Urology, Sri Ramachandra Institute of Higher Education & Research, Chennai, 600106, India
7 shared publications - Vikesh Agrawal
Department of Pediatric Surgery, Netaji Subhash Chandra Bose Government Medical College, Jabalpur, Madhya Pradesh, India
7 shared publications V.V.S. Chandrasekharam
Pediatric Surgery & Pediatric Urology, Ankura Hospital for Children, Hyderabad, India
5 shared publicationsR. D. Spicer
Department of Paediatric Surgery, Royal Hospital for Sick Children, Bristol, UK
4 shared publications
Latest Publications
- 28 September 2026
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 23 (1)
Laparoscopic pyeloplasty in posteriorly malrotated renal pelvis: Preoperative clues, laparoscopic challenges, and technical solutions
- 28 September 2026
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 23 (1)
Laparoscopic pyeloplasty in posteriorly malrotated renal pelvis: Preoperative clues, laparoscopic challenges, and technical solutions
- 22 September 2026
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1) , 686
Oral solifenacin suspension in the management valve bladder: a pilot study
Aims This pilot study aims to evaluate the efficacy, safety, and tolerability of oral suspension form of solifenacin in children with valve bladder. Methods Children who developed valve bladder after primary posterior urethral valve (PUV) fulguration were prospectively recruited between 2021 and 2025. Inclusion required features of detrusor overactivity, persistent hydronephrosis, or daytime wetting, with exclusion of residual valves/ infection. Solifenacin suspension was administered at 0.07 mg/kg once daily for 12 months. Subjective parameters included voiding frequency, wetting episodes, and side effects. Objective measures included voided volume as a percentage of age-adjusted expected bladder capacity (VV/EBC), detrusor pressure (Pdet‑max), maximum cystometric capacity (MCC), bladder compliance, Society for Fetal Urology (SFU) hydronephrosis grade, and ureteral diameter. Results A total of 47 children with a median age of 3 (0.5–5) years presenting with valve bladder features were administered oral solifenacin suspension. At a median follow-up of 16 months, urinary frequency decreased significantly from 12.8 to 7.4 episodes/day (p = 0.001); wetting episodes declined from 4.7 to 1.8/day (p = 0.01); VV/EBC improved from 34% to 60% (p = 0.001); SFU hydronephrosis grade reduced from 3.5 to 2.8 (p = 0.003), ureteral diameter from 11.6 mm to 10.2 mm (p = 0.039). Urodynamic assessment showed a significant decline in Pdet-max from 39.2 to 29.3 (p = 0.001), alongside significant improvements in mean bladder compliance/ cystometric capacity. Treatment was well tolerated, with no major adverse effects. Conclusions This pilot study reports the efficacy, safety, and tolerability of oral suspension form of solifenacin in children with valve bladder. Further larger studies are warranted.
- 22 September 2026
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1) , 686
Oral solifenacin suspension in the management valve bladder: a pilot study
Aims This pilot study aims to evaluate the efficacy, safety, and tolerability of oral suspension form of solifenacin in children with valve bladder. Methods Children who developed valve bladder after primary posterior urethral valve (PUV) fulguration were prospectively recruited between 2021 and 2025. Inclusion required features of detrusor overactivity, persistent hydronephrosis, or daytime wetting, with exclusion of residual valves/ infection. Solifenacin suspension was administered at 0.07 mg/kg once daily for 12 months. Subjective parameters included voiding frequency, wetting episodes, and side effects. Objective measures included voided volume as a percentage of age-adjusted expected bladder capacity (VV/EBC), detrusor pressure (Pdet‑max), maximum cystometric capacity (MCC), bladder compliance, Society for Fetal Urology (SFU) hydronephrosis grade, and ureteral diameter. Results A total of 47 children with a median age of 3 (0.5–5) years presenting with valve bladder features were administered oral solifenacin suspension. At a median follow-up of 16 months, urinary frequency decreased significantly from 12.8 to 7.4 episodes/day (p = 0.001); wetting episodes declined from 4.7 to 1.8/day (p = 0.01); VV/EBC improved from 34% to 60% (p = 0.001); SFU hydronephrosis grade reduced from 3.5 to 2.8 (p = 0.003), ureteral diameter from 11.6 mm to 10.2 mm (p = 0.039). Urodynamic assessment showed a significant decline in Pdet-max from 39.2 to 29.3 (p = 0.001), alongside significant improvements in mean bladder compliance/ cystometric capacity. Treatment was well tolerated, with no major adverse effects. Conclusions This pilot study reports the efficacy, safety, and tolerability of oral suspension form of solifenacin in children with valve bladder. Further larger studies are warranted.
- 21 September 2026
- Published by Wiley in Neurourology and Urodynamics
Sacral Transcutaneous Electrical Nerve Stimulation Versus Oxybutynin in Children With Overactive Bladder: A Prospective Randomized Controlled Trial
Aims: The aim of this RCT is to compare the efficacy of sacral transcutaneous electrical nerve stimulation (TENS) with oxybutynin in children with overactive bladder (OAB), focusing on subjective & objective treatment response, adverse effects, and relapse rates. Materials and Methods: In this prospective randomized controlled study, 82 children aged 5–18 years with refractory OAB were randomized to receive either sacral TENS (30 sessions; 20 min each (10 Hz) daily; for 4 weeks) or oral oxybutynin (0.2 mg/kg/day for 4 weeks). Outcomes were assessed using subjective response categories based on bladder diaries and objective measures including the Overactive Bladder Index (OABI) and Dysfunctional Voiding Symptom Score (DVSS). Adverse effects and relapse during 6–12 months of follow‐up were recorded. Results: There was no significant difference between age/sex distributions between the groups. Median follow‐up was 9 (6–12) months. Complete response was significantly higher with TENS than oxybutynin (68.3% vs. 31.7%; OR 4.63, 95% CI 1.8–11.7; p = 0.001). Mean improvement in OABI (4.6 ± 1.4 vs. 3.7 ± 1.0; p = 0.001) and DVSS (8.8 ± 1.5 vs. 5.7 ± 1.3; p = 0.001) favored TENS. Adverse effects (4.9% vs. 46.3%) and relapse rates (7.3% vs. 29.3%) were significantly lower with TENS. Conclusion: Sacral TENS was associated with higher response rates and fewer adverse effects than oxybutynin in this cohort supporting its role as an effective and well‐tolerated therapeutic option for pediatric OAB. Further larger trials are warranted.
- 21 September 2026
- Published by Wiley in Neurourology and Urodynamics
Sacral Transcutaneous Electrical Nerve Stimulation Versus Oxybutynin in Children With Overactive Bladder: A Prospective Randomized Controlled Trial
Aims: The aim of this RCT is to compare the efficacy of sacral transcutaneous electrical nerve stimulation (TENS) with oxybutynin in children with overactive bladder (OAB), focusing on subjective & objective treatment response, adverse effects, and relapse rates. Materials and Methods: In this prospective randomized controlled study, 82 children aged 5–18 years with refractory OAB were randomized to receive either sacral TENS (30 sessions; 20 min each (10 Hz) daily; for 4 weeks) or oral oxybutynin (0.2 mg/kg/day for 4 weeks). Outcomes were assessed using subjective response categories based on bladder diaries and objective measures including the Overactive Bladder Index (OABI) and Dysfunctional Voiding Symptom Score (DVSS). Adverse effects and relapse during 6–12 months of follow‐up were recorded. Results: There was no significant difference between age/sex distributions between the groups. Median follow‐up was 9 (6–12) months. Complete response was significantly higher with TENS than oxybutynin (68.3% vs. 31.7%; OR 4.63, 95% CI 1.8–11.7; p = 0.001). Mean improvement in OABI (4.6 ± 1.4 vs. 3.7 ± 1.0; p = 0.001) and DVSS (8.8 ± 1.5 vs. 5.7 ± 1.3; p = 0.001) favored TENS. Adverse effects (4.9% vs. 46.3%) and relapse rates (7.3% vs. 29.3%) were significantly lower with TENS. Conclusion: Sacral TENS was associated with higher response rates and fewer adverse effects than oxybutynin in this cohort supporting its role as an effective and well‐tolerated therapeutic option for pediatric OAB. Further larger trials are warranted.
- Open Access
- 3 September 2026
- Published by Wolters Kluwer Health in Journal of Indian Association of Pediatric Surgeons
- Vol. 31 (5) , 870-872
Single-stage Reconstruction in a Rare Case of Female Caudal Duplication Syndrome
A BSTRACT: Caudal duplication syndrome is exceptionally rare. We report a female infant with complex genitourinary and colorectal duplication managed by detailed imaging and single-stage definitive reconstruction. Excision of nonfunctional duplicated organs, transureteroureterostomy, bowel reconstruction, and perineal unification achieved good urinary, bowel, and cosmetic outcomes at short-term follow-up without significant complications.
- 3 September 2026
- Published by Wolters Kluwer Health in Journal of Indian Association of Pediatric Surgeons
- Vol. 31 (5) , 870-872
Open AccessSingle-stage Reconstruction in a Rare Case of Female Caudal Duplication Syndrome
A BSTRACT: Caudal duplication syndrome is exceptionally rare. We report a female infant with complex genitourinary and colorectal duplication managed by detailed imaging and single-stage definitive reconstruction. Excision of nonfunctional duplicated organs, transureteroureterostomy, bowel reconstruction, and perineal unification achieved good urinary, bowel, and cosmetic outcomes at short-term follow-up without significant complications.
- 3 August 2026
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 22 (5)
Response to Letter to the Editor re: "Moving beyond meatal location: The case for a ten-point severity grading system in hypospadias"
- 3 August 2026
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 22 (5)
Response to Letter to the Editor re: "Moving beyond meatal location: The case for a ten-point severity grading system in hypospadias"
- Open Access
- 27 July 2026
- Published by Wolters Kluwer Health in Journal of Indian Association of Pediatric Surgeons
- Vol. 31 (6) , 949-954
Histological Characteristics in XY and 45,X/46,XY Differences of Sex Development and their Role in Clinical Decisions: A 10-year Retrospective Study
A BSTRACT: Background/Aims: Differences of sex development (DSD) are complex conditions requiring careful balance between malignancy risk and preservation of fertility and hormonal function. Histological assessment of gonads plays a key role in guiding management, particularly in XY DSD and 45,X/46,XY mixed gonadal dysgenesis (MGD). This study evaluates gonadal and Müllerian histology and correlates findings with clinical decision-making. Methods: A retrospective analysis was performed on histological specimens from patients with XY DSD, MGD, ovotesticular DSD (OTD), and persistent Müllerian duct syndrome (PMDS) managed between 2015 and 2025 at two centres. Patients underwent gonadal biopsy or gonadectomy. Specimens were assessed for gonadal immaturity, dysplasia, and neoplasia. Symptomatic Müllerian remnants were excised. Clinical data, including karyotype, surgical management, and sex of rearing, were analyzed. Results: Twenty-six patients were included (12 XY DSD, 7 MGD, 3 OTD, 4 PMDS). Median age at biopsy was 2 years. In XY DSD, no premalignant changes were identified, 75% showed immature elements; all underwent gonadopexy. In MGD, all streak gonads were excised; 2/7 showed immature/dysplastic elements. OTD cases revealed mature ovarian/testicular tissue on polar biopsy. Müllerian remnants in PMDS contained smooth muscle and uterine elements without dysplasia. Most patients (23/26) were reared male. Over a median 9-year follow-up, no malignancy was observed. Conclusions: High rates of gonadal immaturity in the small cohort of XY DSD in this study support the practice of early gonadopexy. In contrast, dysplasia in MGD supports prophylactic gonadectomy recommended in the literature. Histological evaluation provides objective data to guide DSD management.
- 27 July 2026
- Published by Wolters Kluwer Health in Journal of Indian Association of Pediatric Surgeons
- Vol. 31 (6) , 949-954
Open AccessHistological Characteristics in XY and 45,X/46,XY Differences of Sex Development and their Role in Clinical Decisions: A 10-year Retrospective Study
A BSTRACT: Background/Aims: Differences of sex development (DSD) are complex conditions requiring careful balance between malignancy risk and preservation of fertility and hormonal function. Histological assessment of gonads plays a key role in guiding management, particularly in XY DSD and 45,X/46,XY mixed gonadal dysgenesis (MGD). This study evaluates gonadal and Müllerian histology and correlates findings with clinical decision-making. Methods: A retrospective analysis was performed on histological specimens from patients with XY DSD, MGD, ovotesticular DSD (OTD), and persistent Müllerian duct syndrome (PMDS) managed between 2015 and 2025 at two centres. Patients underwent gonadal biopsy or gonadectomy. Specimens were assessed for gonadal immaturity, dysplasia, and neoplasia. Symptomatic Müllerian remnants were excised. Clinical data, including karyotype, surgical management, and sex of rearing, were analyzed. Results: Twenty-six patients were included (12 XY DSD, 7 MGD, 3 OTD, 4 PMDS). Median age at biopsy was 2 years. In XY DSD, no premalignant changes were identified, 75% showed immature elements; all underwent gonadopexy. In MGD, all streak gonads were excised; 2/7 showed immature/dysplastic elements. OTD cases revealed mature ovarian/testicular tissue on polar biopsy. Müllerian remnants in PMDS contained smooth muscle and uterine elements without dysplasia. Most patients (23/26) were reared male. Over a median 9-year follow-up, no malignancy was observed. Conclusions: High rates of gonadal immaturity in the small cohort of XY DSD in this study support the practice of early gonadopexy. In contrast, dysplasia in MGD supports prophylactic gonadectomy recommended in the literature. Histological evaluation provides objective data to guide DSD management.
- 15 July 2026
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 22 (6) , 106155
Holmium laser ablation (HOLA) of posterior urethral valves in preterm newborns
- 15 July 2026
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 22 (6) , 106155
Holmium laser ablation (HOLA) of posterior urethral valves in preterm newborns
- 8 July 2026
- Published by Springer Nature in Journal of Pediatric Endoscopic Surgery
- Vol. 8 (3) , 135-141
Robot-assisted versus conventional laparoscopic surgery in pediatric urology: a narrative review for a balanced approach
- 8 July 2026
- Published by Springer Nature in Journal of Pediatric Endoscopic Surgery
- Vol. 8 (3) , 135-141
Robot-assisted versus conventional laparoscopic surgery in pediatric urology: a narrative review for a balanced approach